- Home
- NNBR vs KLRS Comparison
NNBR vs KLRS Comparison
Compare NNBR & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNBR
- KLRS
- Stock Information
- Founded
- NNBR 1980
- KLRS 2019
- Country
- NNBR United States
- KLRS United States
- Employees
- NNBR N/A
- KLRS N/A
- Industry
- NNBR Industrial Machinery/Components
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NNBR Industrials
- KLRS Health Care
- Exchange
- NNBR Nasdaq
- KLRS Nasdaq
- Market Cap
- NNBR 149.8M
- KLRS 129.0M
- IPO Year
- NNBR 1994
- KLRS N/A
- Fundamental
- Price
- NNBR $1.71
- KLRS $3.48
- Analyst Decision
- NNBR
- KLRS Buy
- Analyst Count
- NNBR 0
- KLRS 1
- Target Price
- NNBR N/A
- KLRS N/A
- AVG Volume (30 Days)
- NNBR 196.9K
- KLRS 62.3K
- Earning Date
- NNBR 05-07-2025
- KLRS 05-19-2025
- Dividend Yield
- NNBR N/A
- KLRS N/A
- EPS Growth
- NNBR N/A
- KLRS N/A
- EPS
- NNBR N/A
- KLRS N/A
- Revenue
- NNBR $448,780,000.00
- KLRS N/A
- Revenue This Year
- NNBR $0.82
- KLRS N/A
- Revenue Next Year
- NNBR $6.29
- KLRS N/A
- P/E Ratio
- NNBR N/A
- KLRS N/A
- Revenue Growth
- NNBR N/A
- KLRS N/A
- 52 Week Low
- NNBR $1.58
- KLRS $4.19
- 52 Week High
- NNBR $4.67
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- NNBR 38.01
- KLRS N/A
- Support Level
- NNBR $1.76
- KLRS N/A
- Resistance Level
- NNBR $1.99
- KLRS N/A
- Average True Range (ATR)
- NNBR 0.15
- KLRS 0.00
- MACD
- NNBR 0.01
- KLRS 0.00
- Stochastic Oscillator
- NNBR 20.45
- KLRS 0.00
About NNBR NN Inc.
NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components. It operates in two business segments: mobile solutions and power solutions. The mobile solutions segment involves growth in the general industrial and automotive end markets. Its power solutions segment involves growth in the electrical and aerospace and defense end markets. It also operates in China, Mexico, Brazil, Germany, and other countries.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.